EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Promoting tumor antigen presentation unleashes therapeutic efficacy of Tgfbr2 -deficient TCR-engineered T cells in pancreatic ductal adenocarcinoma

Alexander K Tsai, Meagan R Rollins, Madeline A Ellefson, Zoe C Schmiechen, Adam L Burrack, Ayaka Hulbert, Guhan Qian, Hongrong Zhang, Eduardo Cruz-Hinojoza, Jonah Z Butler, Jason S Mitchell, Olivia C Ghirardelli Smith und 8 weitere

Journal for ImmunoTherapy of Cancer · 2026-10 · 14 (10) · e015489

DOI: 10.1136/jitc-2026-015489 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 29.10.2026. Verfasst von Alexander K Tsai und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, Minnesota, USA. Die Arbeit nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIAID NIH HHS, NCI NIH HHS, American Cancer Society.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Pancreatic ductal adenocarcinoma (PDA) is a lethal malignancy with limited therapeutic options. Adoptive cell therapy (ACT) using tumor-reactive T cell receptor-engineered T cells (TCR-T) is a promising therapeutic modality for targeting PDA. However, additional strategies are needed to overcome the suppressive tumor microenvironment (TME) that impairs T cell persistence and function. Tumor growth factor-β (TGFβ) is a prominent immunosuppressive component of the TME, but is also believed to be critical for T cell memory.

Methods

We develop aggressive immunocompetent orthotopic KrasLSL-G12D/+;Trp53LSL-R172H/+;p48-Cre (KPC) PDA mouse models to identify obstacles to sustained activity of TCR-T cell therapy targeting the native tumor antigen, mesothelin (Msln). During ACT, we track TCR-T cell fate, function, antitumor effects, and interactions with type I dendritic cells using flow cytometry, two-photon microscopy, and live-cell imaging. Based on an abundance of TGFβ and a halt in TCR-T cell differentiation in orthotopic tumors, TCR-T cells with defective Tgfbr2 are tested in a new model, where peptide-major histocompatibility complex-I (pMHC-I) is incrementally augmented on KPC tumor cells.

Results

TCR-T cells accumulated in orthotopic PDA but were rendered dysfunctional despite lacking features of exhaustion. KPC tumor cells express minimal constitutive MHC-I, resulting in suboptimal recognition by TCR-T cells. Modestly increasing pMHC-I on KPC tumor cells restored canonical differentiation of TCR-T cells into PD-1+ progenitor exhausted (TPEX) in PDA, but failed to rescue interferon-γ (IFNγ) production. TGFβ was enriched in tumor nests, and deletion of Tgfbr2 in TCR-T cells enhanced dendritic cell interactions, reduced intratumoral TGFβ deposition, restored IFNγ production, and improved therapeutic efficacy without compromising TCR-T cell longevity or tissue residency.

Conclusions

Modestly enhancing tumor-intrinsic pMHC-I unleashes therapeutic efficacy and functionality of Tgfbr2-disrupted TCR-T cells in PDA.

Schlagwörter

Stichwörter der Autor:innen

Adoptive cell therapy - ACTEscape/evasionGastrointestinal CancerMajor histocompatibility complex - MHCT cell

Autor:innen und Institutionen

  • Department of Medicine, Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, Minnesota, USA.
  • Center for Immunology, University of Minnesota, Minneapolis, Minnesota, USA.
  • Department of Microbiology and Immunology, University of Minnesota, Minneapolis, Minnesota, USA.
  • Program in Immunology and Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
  • Department of Biomedical Engineering, University of Minnesota, Minneapolis, Minnesota, USA.
  • Center for Multiparametric Imaging of Tumor Immune Microenvironments, University of Minnesota, Minneapolis, Minnesota, USA.

Förderung

  • NIAID NIH HHS
  • NCI NIH HHS
  • American Cancer Society
  • American Association for Cancer Research
  • National Cancer Institute
  • National Institute of Allergy and Infectious Diseases
  • Congressionally Directed Medical Research Programs
  • Masonic Cancer Center, University of Minnesota

Zitieren

APA

Tsai, A. K., Rollins, M. R., Ellefson, M. A., Schmiechen, Z. C., Burrack, A. L., Hulbert, A., Qian, G., Zhang, H., Cruz-Hinojoza, E., Butler, J. Z., Mitchell, J. S., Ghirardelli Smith, O. C., O'Flanagan, S. D., Krause, J., Hickok, G. H., Provenzano, P. P., Masopust, D., Hingorani, S. R., Greenberg, P. D., & Stromnes, I. M. (2026). Promoting tumor antigen presentation unleashes therapeutic efficacy of Tgfbr2 -deficient TCR-engineered T cells in pancreatic ductal adenocarcinoma. Journal for ImmunoTherapy of Cancer, 14(10), e015489. https://doi.org/10.1136/jitc-2026-015489

Vancouver

Tsai AK, Rollins MR, Ellefson MA, Schmiechen ZC, Burrack AL, Hulbert A, et al. Promoting tumor antigen presentation unleashes therapeutic efficacy of Tgfbr2 -deficient TCR-engineered T cells in pancreatic ductal adenocarcinoma. Journal for ImmunoTherapy of Cancer. 2026;14(10):e015489. doi:10.1136/jitc-2026-015489

BibTeX
@article{Tsai2026,
  author = {Tsai, Alexander K and Rollins, Meagan R and Ellefson, Madeline A and Schmiechen, Zoe C and Burrack, Adam L and Hulbert, Ayaka and Qian, Guhan and Zhang, Hongrong and Cruz-Hinojoza, Eduardo and Butler, Jonah Z and Mitchell, Jason S and Ghirardelli Smith, Olivia C and O'Flanagan, Stephen D and Krause, Jenny and Hickok, Grant H and Provenzano, Paolo P and Masopust, David and Hingorani, Sunil R and Greenberg, Philip D and Stromnes, Ingunn M},
  title = {Promoting tumor antigen presentation unleashes therapeutic efficacy of Tgfbr2 -deficient TCR-engineered T cells in pancreatic ductal adenocarcinoma},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2026},
  volume = {14},
  number = {10},
  pages = {e015489},
  doi = {10.1136/jitc-2026-015489}
}
Kostenlos starten →